Triclofos
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Using the drug-repurposing-evaluation-report skill implicitly per the specified template (no other skill applies — this is a direct content-generation task using the fixed prompt format).
Triclofos: From Sedative-Hypnotic Agent to Insomnia
One-Sentence Summary
Triclofos is the prodrug of trichloroethanol — the same active metabolite as chloral hydrate — and has historically been used as a sedative-hypnotic, though it is not currently marketed or registered in India. The TxGNN model’s top prediction for this drug is Insomnia (disease), essentially reaffirming its known historical pharmacological role rather than identifying a truly novel indication. Direct supporting evidence for this exact entry is currently limited (0 clinical trials, 0 literature citations attached to the “insomnia” node itself), though closely related synonym terms and adjacent indications (sleep disorder, anxiety/sedation) are supported by multiple older RCTs and case reports.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No structured registration or indication data available (drug not currently marketed in India; original MOA and indication fields are data gaps) |
| Predicted New Indication | Insomnia (disease) |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L4 (mechanism/preclinical-level support) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, Triclofos (triclofos sodium) is a phosphorylated derivative of chloral hydrate, functioning as a prodrug that is metabolized to trichloroethanol — the identical active metabolite produced by chloral hydrate itself. Trichloroethanol acts on the GABA-A receptor complex, producing sedative and hypnotic effects, a mechanism that is well established in the pharmacology literature even though it is not recorded in the structured original_moa field here.
Because trichloroethanol is the shared active moiety of both chloral hydrate and triclofos, and chloral hydrate has a long clinical history as a sedative-hypnotic, the predicted indication of “insomnia” is not so much a novel repurposing hypothesis as a restatement of the drug’s traditional pharmacological class effect. This is corroborated by literature attached to the closely related synonym node “sleep disorder, initiating and maintaining sleep,” which includes a 1979 double-blind crossover hypnotic trial (PMID 387491) directly comparing triclofos sodium to nitrazepam for insomnia, and a 1972 case-series report (PMID 4567567) titled “Triclofos sodium (Triclos) for insomnia.”
Additional indirect support comes from a substantial body of pediatric procedural-sedation and premedication RCTs (attached to the “anxiety” node) comparing oral triclofos to midazolam, diazepam, flunitrazepam, and hydroxyzine. These studies confirm triclofos’s clinically effective sedative-hypnotic activity across decades of use, even though their endpoints (procedural sedation, preoperative anxiolysis) are not identical to a chronic insomnia indication. Overall, the mechanistic rationale is strong, but it should be read as validating an already-known drug class effect rather than uncovering a new therapeutic use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for this specific indication entry (insomnia). Note: closely related synonym terms in this evidence pack (e.g., “sleep disorder, initiating and maintaining sleep”) do carry supporting literature — see the rationale discussion above.
India Market Information
Triclofos currently has no registered products in India — 0 authorizations are on record, and market status is listed as Not Marketed.
Safety Considerations
Please refer to the package insert for safety information. Structured warnings, contraindications, and drug-interaction data are not currently available for this entry, and this gap has been flagged as Blocking (DG001) for safety evaluation purposes — see Conclusion below.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The predicted indication is well-supported mechanistically (shared active metabolite with chloral hydrate, a known hypnotic class effect) and consistent with historical literature, but this evidence pack lacks any registered product, label warnings/contraindications, or trials/literature directly attached to the insomnia entry itself. A blocking data gap (missing warnings/contraindications) prevents a preliminary safety assessment (S1), so the candidate cannot advance past a research question stage yet.
To proceed, the following is needed:
- Official label warnings and contraindications (via source regulatory agency, since India has no registration to reference)
- Confirmed mechanism of action data from DrugBank
- Clarification of current global marketing/registration status for triclofos
- A safety monitoring plan addressing known chloral-hydrate-class risks (hepatic metabolism, respiratory depression, cardiac arrhythmia with prolonged/high-dose use), particularly given its historical use in pediatric populations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.